Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGNE BeiGene		$194.32	$141.31 ▼ $248.16	$18.03B	0.57	296,389 shs	331,608 shs
BNTX BioNTech	$102.43 -1.7%	$100.82	$76.53 ▼ $131.49	$24.58B	1.07	912,192 shs	984,983 shs
TAK Takeda Pharmaceutical	$15.03 -1.7%	$14.81	$12.58 ▼ $15.37	$47.81B	0.39	1.87 million shs	1.67 million shs
VTRS Viatris	$8.47 +0.6%	$8.68	$6.85 ▼ $13.55	$10.11B	0.91	9.96 million shs	16.09 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+19.99%
BNTX BioNTech	+0.14%	-9.41%	+14.38%	-13.84%	+17.26%
TAK Takeda Pharmaceutical	0.00%	+0.73%	+2.72%	+11.74%	+16.77%
VTRS Viatris	+0.96%	+7.81%	-3.33%	-26.27%	-27.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGNE BeiGene	1.2388 of 5 stars	3.4	0.0	0.0	0.0	0.8	0.6
BNTX BioNTech	2.551 of 5 stars	4.4	2.0	0.0	2.8	0.8	0.0
TAK Takeda Pharmaceutical	3.1708 of 5 stars	0.0	4.0	2.5	3.4	0.0	2.5
VTRS Viatris	1.832 of 5 stars	1.9	3.0	2.5	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	40.03% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
VTRS Viatris	1.75	Reduce	$10.50	23.97% Upside

Current Analyst Ratings Breakdown

Latest VTRS, TAK, BNTX, and BGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
3/7/2025	VTRS Viatris	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $13.00
3/5/2025	VTRS Viatris	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$14.00 ➝ $10.00
2/28/2025	VTRS Viatris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$12.00 ➝ $9.00
2/28/2025	VTRS Viatris	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$11.00 ➝ $10.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
BNTX BioNTech	$2.75B	8.93	$4.41 per share	23.25	$92.17 per share	1.11
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.52 per share	4.27	$15.39 per share	0.98
VTRS Viatris	$14.74B	0.69	$4.01 per share	2.11	$17.06 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.56	9.11	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)
VTRS Viatris	$54.70M	-$0.53	N/A	3.30	N/A	-5.87%	16.46%	7.09%	5/8/2025 (Estimated)

Latest VTRS, TAK, BNTX, and BGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	VTRS Viatris	$0.52	N/A	N/A	N/A	$3.30 billion	N/A
5/5/2025	Q1 2025	BNTX BioNTech	-$2.68	N/A	N/A	N/A	$175.90 million	N/A
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 2024	VTRS Viatris	$0.57	$0.54	-$0.03	-$0.43	$3.60 billion	$3.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.49%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.53%	-8.36%	132.50%	N/A
VTRS Viatris	$0.48	5.67%	+13.30%	N/A	N/A

Latest VTRS, TAK, BNTX, and BGNE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/24/2025	VTRS Viatris	quarterly	$0.12	5.2%	3/10/2025	3/10/2025	3/18/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGNE BeiGene	0.05	1.93	1.72
BNTX BioNTech	0.01	7.33	7.21
TAK Takeda Pharmaceutical	0.63	1.31	0.72
VTRS Viatris	0.82	1.51	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGNE BeiGene	48.55%
BNTX BioNTech	15.52%
TAK Takeda Pharmaceutical	9.17%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
BGNE BeiGene	7.43%
BNTX BioNTech	19.20%
TAK Takeda Pharmaceutical	0.04%
VTRS Viatris	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable
VTRS Viatris	37,000	1.19 billion	1.19 billion	Optionable

VTRS, TAK, BNTX, and BGNE Headlines

Recent News About These Companies

Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS

May 1 at 7:30 PM | accessnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

May 1 at 7:00 PM | accessnewswire.com

Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS

May 1 at 5:45 PM | accessnewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS

May 1 at 5:28 PM | globenewswire.com

Investors in Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS

May 1 at 3:45 PM | accessnewswire.com

Shareholders that lost money on Viatris Inc. (VTRS) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

May 1 at 12:52 PM | globenewswire.com

Levi & Korsinsky Notifies Shareholders of Viatris Inc. (VTRS) of a Class Action Lawsuit and an Upcoming Deadline

May 1 at 12:30 PM | accessnewswire.com

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

May 1 at 11:06 AM | zacks.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Viatris Inc. (VTRS) Shareholders

May 1 at 11:00 AM | accessnewswire.com

VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS

May 1 at 10:39 AM | globenewswire.com

Lost Money on Viatris Inc. (VTRS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

May 1 at 8:15 AM | accessnewswire.com

VTRS COURT DEADLINE: Viatris Inc. (NASDAQ:VTRS) Investors with Losses have Until June 3 before the Expiration of the Class Action Deadline – Contact BFA Law

May 1 at 8:08 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

May 1 at 8:00 AM | accessnewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Viatris Inc. (VTRS) Shareholders

May 1 at 7:30 AM | accessnewswire.com

VTRS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

May 1 at 7:00 AM | accessnewswire.com

June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS

May 1 at 5:45 AM | prnewswire.com

Viatris Inc. (VTRS): Among the Worst Performing Stocks in S&P 500 So Far in 2025

April 30 at 8:17 PM | insidermonkey.com

Viatris Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS

April 30 at 8:00 PM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit – VTRS

April 30 at 4:15 PM | accessnewswire.com

VTRS ANNOUNCEMENT: Viatris Inc. Investors May Have Been Affected by Fraud - Contact BFA Law Before June 3 Court Deadline

April 30 at 3:36 PM | accessnewswire.com

2 Generic Drug Stocks Ready to Surge in 2025

November 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
Buffett’s Next Oil Bet: Why Occidental Is Different
By Jea Yu | April 8, 2025
View Buffett’s Next Oil Bet: Why Occidental Is Different
United States Steel's Crash: An Unmissable Buying Opportunity
By Gabriel Osorio-Mazilli | April 11, 2025
View United States Steel's Crash: An Unmissable Buying Opportunity
IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
By Leo Miller | April 12, 2025
View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
AI Takes Over Search: Is Google's Dominance At Risk?
By Ryan Hasson | April 7, 2025
View AI Takes Over Search: Is Google's Dominance At Risk?

VTRS, TAK, BNTX, and BGNE Company Descriptions

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BioNTech NASDAQ:BNTX

$102.43 -1.72 (-1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$102.91 +0.48 (+0.47%)

As of 07:56 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Takeda Pharmaceutical NYSE:TAK

$15.02 -0.27 (-1.73%)

Closing price 03:59 PM Eastern

Extended Trading

$15.12 +0.10 (+0.66%)

As of 06:16 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Viatris NASDAQ:VTRS

$8.47 +0.05 (+0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$8.43 -0.04 (-0.53%)

As of 07:59 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time